Qiagen N.V. (QGEN)

NYSE: QGEN · IEX Real-Time Price · USD
47.39
-0.66 (-1.37%)
Aug 18, 2022 4:00 PM EDT - Market closed
-1.37%
Market Cap 10.79B
Revenue (ttm) 2.26B
Net Income (ttm) 514.30M
Shares Out 227.69M
EPS (ttm) 2.21
PE Ratio 21.44
Forward PE 22.73
Dividend n/a
Ex-Dividend Date n/a
Volume 638,257
Open 47.88
Previous Close 48.05
Day's Range 47.28 - 47.91
52-Week Range 41.32 - 58.00
Beta 0.30
Analysts Buy
Price Target 57.26 (+20.8%)
Earnings Date Jul 27, 2022

About QGEN

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample mate... [Read more...]

Industry Life Sciences Tools & Services
IPO Date Jun 28, 1996
CEO Thierry Bernard
Employees 6,100
Stock Exchange NYSE
Ticker Symbol QGEN
Full Company Profile

Financial Performance

In 2021, Qiagen's revenue was $2.25 billion, an increase of 20.39% compared to the previous year's $1.87 billion. Earnings were $512.60 million, an increase of 42.71%.

Financial Statements

Analyst Forecast

According to 20 analysts, the average rating for QGEN stock is "Buy." The 12-month stock price forecast is 57.26, which is an increase of 20.83% from the latest price.

Price Target
$57.26
(20.83% upside)
Analyst Consensus: Buy
Stock Forecasts

News

QIAGEN Launches Syndromic Test for QIAstat-Dx Device to Combat Global Monkeypox Health Emergency

HILDEN, Germany & GERMANTOWN, Md,--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAstat-Dx Viral Vesicular Panel RUO, the first syndromic te...

QIAGEN (QGEN) Q2 Earnings Top Estimates, Margins Decline

QIAGEN (QGEN) posts better-than-expected results for the second quarter and raises its sales and earnings outlook for 2022 amid the uncertain macroeconomic environment.

QIAGEN adds new biopharma products to QIAcuity digital PCR portfolio and launches Expert Custom Assay Design Service

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today a series of enhancements for its QIAcuity series of digital PCR (dPCR) instruments ...

Qiagen (QGEN) Beats Q2 Earnings and Revenue Estimates

Qiagen (QGEN) delivered earnings and revenue surprises of 13.33% and 3.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

QIAGEN beats outlook for Q2 2022 and raises full-year 2022 outlook

VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the second quarter of 2022 and increased the outlook for full-year 2022. Net sales ...

QIAGEN (QGEN) QCI's Robust Adoption to Enhance Patient Outcome

QIAGEN's (QGEN) QCI platform is expected to significantly streamline NGS data analysis and variant interpretation, and enable swift and confident shift by users from raw NGS data to clinical report.

QIAGEN's Clinical Decision Support Platform QCI Surpasses Three Million NGS Patient Test Cases

REDWOOD CITY, Calif. & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its decision-support software platform QIAGEN Clinical Insights (QCI) has...

QIAGEN N.V. to Release Results for Q2 2022 and Hold Webcast

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. to release results for Q2 2022 and hold Webcast

QIAGEN CEO details how company tracks the spread of COVID through wastewater testing

This segment originally aired on June 6, 2022. QIAGEN CEO Thierry Bernard joins Yahoo Finance Live anchors Brian Cheung and Akiko Fujita to explain how his company is utilizing technology to track the s...

Relation Therapeutics, the Active-Graph Machine Learning Drug Discovery Company, Names David Roblin as CEO and Lindsa...

LONDON--(BUSINESS WIRE)--Relation Therapeutics Closes $25 Million Seed Financing and Names David Roblin as CEO and Lindsay Edwards as CTO

Other symbols: TMO

U.S. CDC Endorses the Use of Digital PCR Technology for Wastewater Surveillance of Infectious Diseases – Including CO...

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it welcomed an endorsement from the National Wastewater Surveillance Syst...

Why Is Qiagen (QGEN) Up 0.1% Since Last Earnings Report?

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?

QIAGEN's Eco-Friendlier Products Earn Prestigious ACT Label

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its recently launched, environmentally friendlier QIAwave nucleic-acid ex...

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

Investors are optimistic about QIAGEN (QGEN), owing to strong international growth and bullish guidance.

QIAGEN (QGEN) Unveils New Enhancements to QIAstat-Dx Portfolio

The launch of QIAstat-Dx Rise and other advancements to the QIAstat-Dx portfolio are expected to strengthen QIAGEN's (QGEN) syndromic testing solutions.

QIAGEN (QGEN) to Acquire Poland-Based Enzymes Manufacturer

The latest acquisition of BLIRT will allow QIAGEN (QGEN) to tap into the high opportunities within the life science industry.

QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-Dx Rise and Enhanced Panels

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAstat-Dx Rise – a high-capacity version of the QIAstat-Dx auto...

QIAGEN Acquires Majority Stake in Enzymes Provider BLIRT S.A.

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has signed agreements to acquire a 96% majority ownership stake in BLI...

QIAGEN Proposes Expansion of Supervisory Board

VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the proposal of Dr. Eva Pisa, a leader in health diagnostics and biotechnology who has ex...

QIAGEN Adds HSV1/2 Herpes Assay With CE-IVD Certification for Use on NeuMoDx Integrated PCR System

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its NeuMoDx HSV 1/2 Quant Assay for the quantification and differentiatio...

QIAGEN (QGEN) Q1 Earnings Surpass Estimates, 2022 View Up

QIAGEN (QGEN) exited first-quarter 2022 with better-than-expected results on strength in the non-COVID product portfolio driving the top line.

Qiagen sees no immediate impact from global supply bottlenecks

U.S.-German biotechnology company Qiagen NV said on Thursday it was not currently affected by global supply chain bottlenecks as it had already been stockpiling supplies at its production facilities ami...

Qiagen (QGEN) Q1 Earnings and Revenues Surpass Estimates

Qiagen (QGEN) delivered earnings and revenue surprises of 12.68% and 6.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

QIAGEN exceeds outlook for Q1 2022, delivers strong 14% CER sales growth from non-COVID products and increases full-y...

VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the first quarter of 2022 and increased the outlook for full-year 2022. Net sales f...

QGEN or ILMN: Which Is the Better Value Stock Right Now?

QGEN vs. ILMN: Which Stock Is the Better Value Option?

Other symbols: ILMN